Publication:


abstract

A pooled analysis of data from four vaccination studies conducted in Europe was undertaken to assess the Immunogenicity of Infanrix™ hexa (DTPa-HBV-IPV/Hib, GlaxoSmithKline Biologicals) when administered in a total of 702 healthy infants at 3, 5 and 11-12 months of age. One month after dose 2, between 96.3% and 100% of subjects had seroprotective antibodies against diphtheria, tetanus, hepatitis B and poliovirus types 1, 2 and 3; 91.7% against Hib and ≥99.0% were seropositive for each pertussis antigen. One month after the third dose, 98.9-100% of subjects were seroprotected/seropositive for all vaccine antigens. Geometric mean antibody concentrations/titres for each vaccine antigen increased by 6.7-52.9 fold after the third vaccine dose. No serious adverse events in DTPa-HBV-IPV/Hib recipients were vaccine related. Infanrix™ hexa induces an adequate immune response after 2-dose primary plus booster doses when administered according to a 3, 5 and 11 months schedule.

Copyright © 2012 Elsevier Ltd. All rights reserved.

Related Articles
Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
Vaccine. 2003
Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
Arístegui J, Dal-Ré R, Díez-Delgado J, Marés J, Casanovas JM, García-Corbeira P, De Frutos E, Van Esso D, Verdaguer J, De la Flor J, et al. Vaccine. 2003 Sep 8; 21(25-26):3593-600.
Review DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa): A Review of its Use as Primary and Booster Vaccination.
Drugs. 2010
Review DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa): A Review of its Use as Primary and Booster Vaccination.
Dhillon S. Drugs. 2010 May 28; 70(8):1021-58.
Immunogenicity and reactogenicity of DTPa-IPV/Hib vaccine co-administered with hepatitis B vaccine for primary and booster vaccination of Taiwanese infants.
J Formos Med Assoc. 2011
Immunogenicity and reactogenicity of DTPa-IPV/Hib vaccine co-administered with hepatitis B vaccine for primary and booster vaccination of Taiwanese infants.
Shao PL, Lu CY, Hsieh YC, Bock HL, Huang LM, Taiwan Infanrix-069 Study Group. J Formos Med Assoc. 2011 Jun; 110(6):415-22.
Review Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
BioDrugs. 2010
Review Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
Dhillon S. BioDrugs. 2010 Oct 1; 24(5):299-302.
Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule.
Eur J Pediatr. 2002
Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule.
Avdicová M, Prikazský V, Hudecková H, Schuerman L, Willems P. Eur J Pediatr. 2002 Nov; 161(11):581-7. Epub 2002 Oct 5.